AstraZeneca PLC (AZN)vsCibus Global LLC (CBUS)
AZN
AstraZeneca PLC
$172.48
+0.48%
HEALTHCARE · Cap: $261.94B
CBUS
Cibus Global LLC
$1.94
0.00%
HEALTHCARE · Cap: $144.13M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1410049% more annual revenue ($60.44B vs $4.29M). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CBUS
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$172.48
$21.48 discount
Margin of Safety
+88.3%
Fair Value
$17.87
Current Price
$1.94
$15.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Revenue surging 62.6% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : CBUS
The strongest argument for CBUS centers on Revenue Growth. Revenue growth of 62.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : CBUS
The primary concerns for CBUS are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 7.78 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while CBUS is a hypergrowth play — different risk/reward profiles.
CBUS carries more volatility with a beta of 1.65 — expect wider price swings.
CBUS is growing revenue faster at 62.6% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. CBUS offers better value entry with a 88.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Cibus Global LLC
HEALTHCARE · BIOTECHNOLOGY · USA
Cibus Global, Ltd., a biotechnology company, develops plant traits for seed industry globally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?